This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this
Franchise video homepage

LATEST CONGRESSES: OUR ACTIVITIES

Past event
ASCO 2019
ASCO 2019
Access materials presented at ASCO; 5 publications and 5 downloads
Past event
WCLC 2019
WCLC 2019
Access materials presented at WCLC; 8 publications and 8 downloads
Past event
ESMO 2019
ESMO 2019
Access materials presented at ESMO; 6 publications and 10 downloads

Physicians´ insights

RESOURCES

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

^Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

 

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: November 2019